Semaglutide offers a promising option for individuals seeking to effectively manage type 2 diabetes and control weight, especially when standard medications are not sufficient
It found a 20% reduction in major adverse cardiovascular events - heart attacks, strokes, and cardiovascular death - with FDA-approved Wegovy in a population with established cardiovascular disease and overweight or obesity
Final Thoughts and Summary Researching a topic this loaded, with this much marketing noise around it, takes real effort and you've clearly put in that effort by reading this far
IGF-1 LR3 accelerates cellular repair, stimulates satellite cells, and increases nutrient utilization
The drug is still in the clinical trial phase
Results are expected to take two to three years